April 14, 2021
Business News

New Study Published in Cephalalgia Identifies Mechanistic Differences Among CGRP Migraine Treatments

TEL AVIV, Israel–()–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) highlights results from the in vitro study “Migraine Therapeutics Differentially Modulate the CGRP Pathway,” which were published online by Cephalalgia, a monthly journal published on behalf of the International Headache Society. These results will also be featured in a future print issue of the journal. This study demonstrated marked differences in the mechanism of blocking the calcitonin gene-related peptide (CGRP) ligand versus the CGRP receptor.

This newly-published study evaluates three distinct mechanistic classes of drugs based on receptor binding, signaling and drug internalization: (1) Monoclonal antibodies against the…

Click here to view the original article.

Related Posts

You might also like ...

Former Coldwell Banker CEO Joins Houwzer Board of Directors
AON Splash Image
K Health, Blackstone Growth, Anthem to Partner on Technology Joint Venture to Advance More Affordable, High-Quality Healthcare
MACKINAC INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mackinac Financial Corporation – MFNC